New Pharmacological options in the therapy of COPD;Neue pharmakologische ansätze in der therapie der COPD

Pneumologie

Volumn 61, Issue 6, 2007, Pages 365-373

  Watz, H ^a   Kanniess, F ^a   Magnussen, Helgo ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ACETYLCYSTEINE; AMFEBUTAMONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERYTHROMYCIN; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 159797; GSK 159802; GSK 597901; GW 642444; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDACATEROL; INFLIXIMAB; INTERLEUKIN 8 ANTIBODY; LAS 34273; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; RETINOID; RIMONABANT; SB 681323; SD 282; SIMVASTATIN; TETRACYCLINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; FORCED EXPIRATORY VOLUME; GENERAL CONDITION IMPROVEMENT; HUMAN; INFLAMMATION; LUNG BLOOD VESSEL; LUNG INFILTRATE; LUNG PARENCHYMA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SMOKING; SYMPTOM;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; MACROLIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES;

EID: 34447641101     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-959156     Document Type: Article

References (136)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis; Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. NIH Publication 2701.2001.http://www.gold.com (accessed November22,2006), 2005
2. Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946
3. Worth H, Buhl R, Cegla U et al. [Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur pneumologie]. Pneumologie 2002; 56: 704-738
4. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053-1061
5. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721
6. Watz H, Magnussen H. [Comorbidities of COPD]. Internist (Berl) 2006; 47: 895-900
7. Anto JM, Vermeire P, Vestbo J et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-994
8. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620
9. Menezes AM, Perez-Padilla R, Jardim JR et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881
10. Lokke A, Lange P, Scharling H et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939
11. WHO. World Helath Report 2002. http://www.who.int/whr/2002, 2005
12. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504
13. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442
14. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276
15. Keatings VM, Collins PD, Scott DM et al. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534
16. Pesci A, Balbi B, Majori M et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380-386
17. 1. Am J Respir Crit Care Med 1997; 155: 852-857
18. Saetta M, Baraldo S, Corbino L et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717
19. Turato G, Zuin R, Miniati M et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110
20. Montuschi P, Kharitonov SA, Ciabattoni G et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58: 585-588
21. Profita M, Giorgi RD, Sala A et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005; 60: 1361-1369
22. Hellermann GR, Nagy SB, Kong X et al. Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respir Res 2002; 3: 22
23. Mio T, Romberger DJ, Thompson AB et al. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 155: 1770-1776
24. Morrison D, Rahman I, Lannan S et al. Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. Am J Respir Crit Care Med 1999; 159: 473-479
25. Takeyama K, Dabbagh K, Jeong SJ et al. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 2000; 164: 1546-1552
26. Tuder RM, Zhen L, Cho CY et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88-97
27. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688
28. Higashimoto Y, Yamagata Y, Iwata T et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005; 25: 885-890
29. Hogg JC, Senior RM. Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema. Thorax 2002; 57: 830-834
30. Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 2002; 30: 98-102
31. Vignola AM, Paganin F, Capieu L et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004; 24: 910-917
32. Ito I, Nagai S, Handa T et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172: 1378-1382
33. Mullen JB, Wright JL, Wiggs BR et al. Reassessment of inflammation of airways in chronic bronchitis. Br Med J (Clin Res Ed) 1985; 291: 1235-1239
34. Saetta M, Di Stefano A, Maestrelli P et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306
35. Saetta M, Turato G, Facchini FM et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1339
36. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004; 59: 992-996
37. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001; 1: 254-258
38. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653
39. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360
40. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003; 28: 555-562
41. Ohnishi K, Takagi M, Kurokawa Y et al. Matrix metalloproteinase- mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998; 78: 1077-1087
42. Tuder RM, Petrache I, Elias JA et al. Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 2003; 28: 551-554
43. Wright JL, Lawson L, Pare PD et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis 1983; 128: 702-707
44. Santos S, Peinado VI, Ramirez J et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1250-1256
45. Peinado VI, Barbera JA Ramirez J et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274: L908-L913
46. Gan WQ, Man SF, Senthilselvan A et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580
47. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519
48. Broekhuizen R, Wouters EF, Creutzberg EC et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22
49. Man SF, Connett JE, Anthonisen NR et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853
50. Dahl M, Vestbo J, Lange P et al. C-reactive Protein as a Predictor of Prognosis in COPD. Am J Respir Crit Care Med 2006; Oct 19; [Epub ahead of print]
51. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004; 364: 791-802
52. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2689-2697
53. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411-1419
54. Noord JA van, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-22
55. Noord JA van, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517
56. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-259
57. Decramer M, Gosselink R, Bartsch P et al. Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax 2005; 60: 343-349
58. Anthonisen NR. Lessons from the Lung Health Study. Proc Am Thorac Soc 2004; 1: 143-145
59. Tashkin DP. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to out understanding. Am J Med 2006; 119: 63-72
60. Surge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303
61. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-781
62. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909
63. Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953
64. Vestbo J, Sorensen T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823
65. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584
66. Sin DD, Wu L, Anderson JA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997
67. Culpitt SV, Maziak W, Loukidis S et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639
68. Keatings VM, Jatakanon A, Worsdell YM et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548
69. Loppow D, Schleiss MB, Kanniess F et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001; 95: 115-121
70. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084-1106
71. Sin DD, Lacy P, York E et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765
72. Kirsten DK, Wegner RE, Jorres RA et al. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993; 104: 1101-1107
73. Cazzola M, Gabriella MM. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study. Respir Med 2006; Oct 20; [Epub ahead of print]
74. Culpitt SV, De Matos C, Russell RE et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1371-1376
75. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731-733
76. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2: 334-339
77. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52S-60S
78. Manning MW, Cassis LA, Dougherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-488
79. Langley SJ et al. Effect of oral doxycycline on MMP-TIMP levels in induced sputum in subjects with COPD. A pilot study. ATS Poster (F18) San Diego, 2005
80. Suzuki T, Yanai M, Yamaya M et al. Erythromycin and common cold in COPD. Chest 2001; 120: 730-733
81. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006; 7: 31-35
82. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4489-4496
83. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
84. Soyseth V, Brekke PH, Smith P et al. Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur Respir J 2006; Oct 18; [Epub ahead of print]
85. Mancini GB, Etminan M, Zhang B et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560
86. Lee JH, Lee DS, Kim EK et al. Simvastatin Inhibits Cigarette Smoking-induced Emphysema and Pulmonary Hypertension in Rat Lungs. Am J Respir Crit Care Med 2005; 172: 987-993
87. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629-636
88. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560
89. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242
90. Meyer A, Buhl R, Kampf S et al. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152: 1055-1060
91. Churg A, Dai J, Tai H et al. Tumor necrosis factor-α is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002; 166: 849-854
92. Churg A, Wang RD, Tai H et al. Tumor necrosis factor-α drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004; 170: 492-498
93. Vernooy JH, Kucukaycan M, Jacobs JA et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218-1224
94. Di Francia M, Barbier D, Mege JL et al. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150: 1453-1455
95. van der Vaart H, Koeter GH, Postma DS et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 465-469
96. Cazzola M, Matera MG, Lotvall J. Ultra long-acting pyagonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775-783
97. 2-agonist, provides 24-hour bronchodilator efficacy in moderate-to-severe COPD. ATS Poster (A118) San Diego, 2006
98. 2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. ERS (P1729) Kopenhagen, 2005
99. 2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma. ERS (P3858) Munich, 2006
100. 2-agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD. ERS (P1920) Kopenhagen, 2005
101. 2-agonist, in patients with stable asthma. ERS (P1728) Kopenhagen, 2005
102. 2-agonist, in moderate to severe COPD. ERS (P1965) Kopenhangen, 2005
103. 2-agonist carmoterol following single rising doses in healthy volunteers. ERS (P3861) Munich, 2006
104. 2-agonist Carmoterol given as a 2 μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma. ERS (P3859) Munich, 2006
105. Schelfhout VJ, Joos GF, Ferrer P et al. Activity of LAS 34273, a new long-acting anticholinergic antagonist. Am J Respir Crit Care Med 2003; 167: A93
106. Singh D, Corris PA, Tansley R. NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD. ERS (P3051) Munich, 2006
107. Hansel TT, Neighbour H, Erin EM et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128: 1974-1979
108. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite((R)) technology. Pulm Pharmacol Ther 2006; May 27; [Epub ahead of print)
109. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167-175
110. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8: 637-642
111. Gamble E, Grootendorst DC, Brightling CE et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976-982
112. Compton CH, Gubb J, Nieman R et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358: 265-270
113. Rabe KF, Bateman ED, O'Donnell D et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-571
114. Gutke HJ, Guse JH, Khobzaoui M et al. AWD-12 - 281 (inhaled) (elbion/GlaxoSmithKline). Curr Opin Investig Drugs 2005; 6: 1149-1158
115. Wise RA, Littner MR, Zangh P et al. Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD). ERS (P3052) Munich, 2006
116. Mahler DA, Huang S, Tabrizi M et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926-934
117. Groenke L, Beeh KM, Cameron R et al. LTB 019, a leukotriene recetor antagonist, has no effect on the levels of neutrophils, mPO, Il-8 and TNF-α in induced sputum of COPD patients in vivo. Am J Respir Crit Care Med 2002; 165: A598
118. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546-553
119. Hipkin RW, Minnicozzi M, Fan X et al. SCH 527123 Is a Selective and Potent CXCR1/2 Antagonist Which Inhibits Neutrophil Recruitment and Mucus Production in Experimental Models of Obstructive Pulmonary Inflammation. ATS (C106) San Diego, 2006
120. Holz O, Jorres RA, Timm P et al. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med 1999; 159: 776-784
121. Holz O, Tal-Singer R, Kanniess F et al. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol 2005; 45: 498-503
122. Smith SJ, Fenwick PS, Nicholson AG et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006; 149: 393-404
123. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679
124. 1: results from the Lung Health Study. Eur Respir J 2005; 25: 1011-1017
125. Harris DS, Anthenelli RM. Expanding treatment of tobacco dependence. Curr Psychiatry Rep 2005; 7: 344-351
126. Dale L, Anthenelli R. Rimonabant as an Aid to Smoking Cessation in Smokers Motivated to Quit. ACC Abstract, March 2004. Circulation 2004; 109: e9017-e9027
127. Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691
128. Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575
129. Vestbo J, Hogg JC. Convergence of the epidemiology and pathology of COPD. Thorax 2006; 61: 86-88
130. Cohn L. Mucus in chronic airway diseases: sorting out the sticky details. J Clin Invest 2006; 116: 306-308
131. The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 1985; 132: 182-185
132. Ong DE, Chytil F. Changes in levels of cellular retinol- and retinoic-acid-binding proteins of liver and lung during perinatal development of rat. Proc Natl Acad Sci USA 1976; 73: 3976-3978
133. Behnke M, Wewel AR, Kirsten D et al. Exercise training raises daily activity stronger than predicted from exercise capacity in patients with COPD. Respir Med 2005; 99: 711-717
134. Roth MD, Connett JE, D'Armiento JM et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006; 130: 1334-1345
135. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221
136. Griffiths MJ, Bonnet D, Janes SM. Stem cells of the alveolar epithelium. Lancet 2005; 366: 249-260